{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Quality of Life (QOL) measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL.","groups":[{"description":"Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I"}],"populationDescription":"QOL was no collected and analyzed for this study due to study termination.","reportingStatus":"POSTED","timeFrame":"after treatment at 6 mos","title":"Quality of Life Assessment as Measured by Functional Assessment of Cancer Therapy (FACT-G) Test","type":"SECONDARY"}